Generic Name:
upadacitinib
Project Status:
Pending
Therapeutic Area:
Crohns disease
Manufacturer:
AbbVie Corporation
Call for patient/clinician input open:
Brand Name:
Rinvoq
Project Line:
Reimbursement Review
Project Number:
SR0775-000
Call for patient/clinician input closed:
Details
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with moderately to severely active Crohn’s disease who have had either an intolerance, inadequate response or demonstrated dependence to corticosteroids, or intolerance, inadequate or loss of response to immunomodulators or to one or more biologic therapies (i.e., tumour necrosis factor-alpha [TNFα] antagonists, gut-selective anti-inflammatory biologics, interleukin 12/23 inhibitors).
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Rinvoq is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had either an intolerance, inadequate response or demonstrated dependence to corticosteroids, or intolerance, inadequate or loss of response to immunomodulators or to one or more biologic therapies (i.e., tumour necrosis factor-alpha [TNFα] antagonists, gut-selective anti-inflammatory biologics, interleukin 12/23 inhibitors)
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.